![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche’s Oncology Drug Tecentriq Grabs European Approval for Breast Cancer
Roche’s Oncology Drug Tecentriq Grabs European Approval for Breast Cancer
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
September 6, 2019
The European Commission has approved Roche’s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) for patients with metastatic triple-negative breast cancer.
The approval was based on the results from a phase 3 clinical trial that showed a statistically significant benefit for Tecentriq in combination with nab-paclitaxel and showed that Tecentriq plus nab-paclitaxel significantly reduced the risk of disease worsening or death compared with nab-paclitaxel alone.
Tecentriq was approved by the FDA in March for use in combination with carboplatin and etoposide as a first-line treatment for adult patients with extensive-stage small cell lung cancer.
Upcoming Events
-
21Oct